Cancer patients in Russia will soon be treated with a domestically developed vaccine in the next few months, according to Alexander Gintsburg - Director of the Institute of Epidemiology and Bi Biology Gamaleya.
The new vaccine is a personalized treatment method, designed to attack malignant tumors using the patient's genetic information.
Developed with the support of artificial intelligence (AI), mRNA technology allows vaccines to be " seconded", suitable for each person's cancer profile, promising targeted therapy and more effective.
All documents have been submitted to the Ministry of Health before and we hope that the Herzen Institute, Blokhin Center and our institute will soon be approved to start producing the first personalized vaccines against melanoma, Gintsburg said at a seminar.
He added that the patient groups have been established and their genetic data has been analyzed, with researchers ready to start treatment within the next month or month and a half.
According to Mr. Gintsburg, the first group to be vaccinated with personalized mRNA vaccine will be 60 melanoma patients, divided equally between the Herzen Moscow Cancer Research Institute and the National Cancer Research Center Blokhin.
In early September, Director of the Federal Agency for Biological Medicine, Ms. Veronika Skvortsova, confirmed that the new cancer vaccine is highly effective in preclinical testing and is ready for clinical application.
Gamaleya Institute is internationally known for developing Sputnik V - Russia's COVID-19 vaccine. Researchers here are also developing a similar HIV vaccine based on mRNA technology used in the treatment of new cancers.
